SAGE-718 Demonstrates Safety, Signs of Improvement in Phase 2 Alzheimer Disease Study - Neurology Live

Sage Therapeutics’ investigational NMDA receptor positive allosteric modulator was well-tolerated, with signs of cognitive and functional improvements reported for patients with AD in the phase 2 LUMINARY study.

According to data presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, Washington, the investigational SAGE-718, a first-in-class positive allosteric modul… [+6035 chars]

full article...